The Research Of A Novel Purified Mumps Virus Antigen Experimental Vaccine

Mumps virus is a member of the family paramyxoviridae, containing asingle negative-strand RNA..Mumps is serologically a monotypic virus. Itis a pathogen of many organ infection, including parotid,nervous systemgenital gland,liver,kidney,heart,joint and so on.. Orchitis,meningitis and encephalitis are more serous than parotitis itself. Sincethe use of a live-attenuated mumps vaccine worldwide during 1960s to 1980s,the incidence of this disease had been reduced dramatically to a'very lowlevel.While effectiveness of the vaccine has been realized from its role inthe mumps endemics worldwide, there are still some incontestable factswhich have attracted more attention in the biological field. Severaloutbreaks of mumps were reported in the United Kingdom (UK),NorthAmerica and Canada, which are highly vaccinated countries. Theseepidemiological reports raised questions about the immune efficacy of thecurrent Mumps virus vaccine. Moreover, many reports of adverse eventsassociated with the mumps vaccine, which mainly include asepticmeningitis and parotitis, also suggest that there is ahigher risk of mumpscomplications in the vaccinated population. Parotitis, the other adverseevent, is the usual clinical presentation in a natural mumps infectionand was also observed to be associated with mumps vaccination. However,despite some reports which did not completely identify the causal linkbetween some adverse events and mumps vaccination, the data provided byseveral large epidemic surveys suggest that development of a better mumpsvaccine is needed.Molecular biology research about MV has shown that the main antigenicaction in virion is its membrane surface glycoproteinhemagglutiinin-neuraminidase (HN).The HN glycoprotein binds to sialyl groups on the host cell membrane during the adsorption phase of theinfection process. The neutralization antibody to HN is just to the MVvirion. Other virus structural proteins are not as important target ofa protective immune response as HN. So we pay more emphasis on HN proteinin the development of a novel purified Mumps virus antigen experimentalvaccine.In this case, it is feasible to search for a novel mumps vaccinethat provide better immunity by selecting the antigen component of thisvirus. That is HN. In other words, development of an HN antigen vaccinemight be achievable for the mumps virus. In the work described here, weattempt to develop a novel purified antigen HN experimental vaccine.In this research, we disrupt condensed inactived Mumps virus, thenuse the methods of sieve chromatography, sepharose CL-4B. we can gettree protein peaks,. The three peaks were collected. Every ingredientwas analyzed by SDS-PAGE,HPLC analysis,Western Blotting,testing forhaemadsorption.. The target protein was identified by N-terminalsequencing of its amino acids. The amount of antigen was measured by amodified howery method.The result is that the first eluted peak containing the viral antigen.The effluent was diluted according to the protein concentration of thefirst antigen active peak to prepare the purified MuV antigen vaccine.Mouse studies suggest that all experimental mice immunized by thisvaccine possess a specific antibody against the mumps virus.The above studing confirms the feasibility of this experimentalvaccine. The purified HN protein ingredient lays foundation for furtherinvestigation.